David J Mazzo
CIK 1334549 · President & CEO · last filed 2026-01-13
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CLBS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
110 ALLEN ROAD, 2ND FLOOR
BASKING RIDGE, NJ 07920
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LSTA | President & CEO | 319,744 | $1.04 | $332.5K | $0 | 8 | 2026-01-13 |
| LISATA THERAPEUTICS, INC. (CLBS) Delisted | Chief Executive Officer | 49,296 | $6.40 | $315.3K | $27.9K | 22 | 2022-09-02 |
| PALISADE BIO, INC. (SNCA) Delisted | Director | — | $9.96 | — | $0 | 2 | 2021-04-26 |
| EYPT | Director | 20,008 | $0.38 | $7.6K | $0 | 10 | 2020-03-03 |
| PALISADE BIO, INC. (CUR) Delisted | Director | — | — | — | $0 | 2 | 2019-10-11 |
| EyePoint, Inc. (PSDV) Delisted | Director | — | — | — | $0 | 11 | 2017-12-19 |
| LISATA THERAPEUTICS, INC. (NBS) Delisted | Chief Executive Officer | 239,543 | — | — | $0 | 3 | 2015-06-04 |
| AVANIR PHARMACEUTICALS, INC. (AVNR) Delisted | Director | 336,394 | — | — | $0 | 8 | 2014-02-14 |
| Tobira Therapeutics, Inc. (RGDO) Delisted | Chief Executive Officer | — | — | — | $0 | 2 | 2014-01-03 |
Recent Filings · Page 6 of 7
68 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2014-12-15 | EyePoint, Inc. (PSDV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2014-02-14 | AVANIR PHARMACEUTICALS, INC. (AVNR) Delisted | Grant (A) | +28,900 | $0 | EDGAR |
| 2014-01-03 | Tobira Therapeutics, Inc. (RGDO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-12-20 | EyePoint, Inc. (PSDV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-08-29 | Tobira Therapeutics, Inc. (RGDO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-02-19 | AVANIR PHARMACEUTICALS, INC. (AVNR) Delisted | Grant (A) | +38,900 | $0 | EDGAR |
| 2012-12-14 | EyePoint, Inc. (PSDV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-02-17 | AVANIR PHARMACEUTICALS, INC. (AVNR) Delisted | Grant (A) | +30,000 | $0 | EDGAR |
| 2011-12-01 | EyePoint, Inc. (PSDV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2011-02-10 | AVANIR PHARMACEUTICALS, INC. (AVNR) Delisted | Grant (A) | +30,000 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.